Charles RAMASSAMY

Key Research Areas
Associated Researchers
Associated Organizations

No partner organizations found.

Recent Research Projects

Redox stress and neuronal functions

2013/14-2017/18 • $125,000 • PI
The non-enzymatic oxidation of polyunsaturated fatty acids (PUFAs) produced a broad range of oxidation products or oxylipidome including many aldehydes, isoprostanes, isoketals, neuroprostanes, and 4-HNE. These products have been widely detected in different biological fluids and tissue samples...

Patents

ANTHOCYANIN FORMULATION AND USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES

A composition comprising a Mixed Anthocyanin Formulation (MAF), wherin said MAF comprises four anthocyanidins/anthocyanins (e.g. kuromarin/cyanidin (Kur), oenin/malvidin (Oen), callistephin/pelargonidin (Cal), and peonidin (Peo) that inhibits several pathological features of neurological diseases/conditions associated with oxidative stress, Amyloid-ß fibril formation and/or neurofibrillary tangle (NFT) formation is disclosed. Also disclosed are methods and uses of such compositions and/or...
Related applications: CA20152951463, WO2015CA50520

SPECIFIC NUTRITIONAL OR THERAPEUTIC AGENT INCLUDING A MIXTURE OF GRAPE AND BLUEBERRY

The invention relates to a nutritional or therapeutic agent which includes a mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium , including: at least 1 % of catechins and epicatechins, given as a percentage by weight based on the total weight of the mixture, preferably at least 5 %; and at least 5 ppm (parts per million in the mixture) of ferulic acid, preferably at least 10 ppm. The invention also relates to the use of said agent in particular for the effects...
Related applications: WO2016EP75905, CA20163002753, FR20150060263, EP20160794958

METHODS, COMPOSITIONS AND KITS FOR THE ASSESSMENT OF MILD COGNITIVE IMPAIRMENT

Methods, compositions and kits for the assessment and management of mild cognitive impairment (MCI) and early stage Alzheimer's disease (AD), and to monitor changes in cognitive functions in subjects over time, are described. The assessment for MCI and early stage AD is based on the level of BDNF, NSE, S100B, PGRN and/or the PGRN/BDNF ratio, in plasma-derived extracellular vesicles (EVs) from a subject.
Related applications: WO2020CA50475